full
border
#666666
http://www.lennonsearch.com/wp-content/themes/smartbox-installable/
http://www.lennonsearch.com/
#26ADE4
style3

Archive for the ‘blog’ Category

14
Jul

Sarepta, jockeying with rival BioMarin to commercialize a treatment for Duchenne muscular dystrophy, is looking to buy up complementary assets to fortify its position. But the company’s better-funded competitor believes its long history in rare disease R&D will give it a leg up as the pair move toward make-or-break FDA decisions. …read more Source: Sarepta […]

14
Jul

The year’s 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013’s top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma’s macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index. …read more […]

13
Jul

Anacor Pharmaceuticals’ topical treatment for eczema came through with positive results in a pair of Phase III trials, propelling the biotech’s shares upward and setting the stage for an FDA application next year. …read more Source: Anacor soars as its eczema cream succeeds in Phase III     

default
Loading posts...
link_magnifier
#5C5C5C
off
fadeInDown
loading
#5C5C5C
off